Can a swift Clot-Buster boost stroke recovery?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years, regardless of sex. * Pre-stroke modified Rankin Scale (mRS) score of 0-1. * Patients with acute ischemic stroke treated within 4.5 hours of symptom onset, who are considered suitable for intravenous thrombolysis with recombinant human prourokinase by the treating investigator. * Written informed consent obtained from the participant or legally authorized representative. Exclusion Criteria: * Known severe hypersensitivity to recombinant human prourokinase. * Other severe neurological, psychiatric, or systemic diseases that may interfere with outcome assessment, adherence, or follow-up. * Uncontrolled severe hypertension before treatment (systolic blood pressure ≥185 mmHg or diastolic blood pressure ≥110 mmHg despite antihypertensive therapy). * Blood glucose \<2.8 mmol/L or \>22.2 mmol/L that remains uncontrolled after correction. * Active internal bleeding or high bleeding risk, including gastrointestinal or urinary tract bleeding within 21 days, major surgery, severe trauma, major organ biopsy within 21 days, non-compressible arterial puncture within 7 days, or other significant bleeding risks. * Known coagulation abnormalities or bleeding tendency, including platelet count \<100 × 10⁹/L, INR \>1.7, clinically significant PT prolongation, clinically significant APTT prolongation, or markedly decreased fibrinogen levels. * Current or recent anticoagulant use associated with increased bleeding risk, including vitamin K antagonists with INR \>1.7, direct thrombin inhibitors or factor Xa inhibitors within 48 hours with abnormal coagulation tests, or heparin within 24 hours with elevated APTT. * History of ischemic stroke, severe head trauma, or myocardial infarction within 3 months. * History of intracranial hemorrhage. * Intracranial or spinal surgery within 3 months. * Known intracranial neoplasm, arteriovenous malformation, large intracranial aneurysm, or other intracranial lesions associated with increased risk of intracranial hemorrhage. * Baseline CT showing intracranial hemorrhage, including intracerebral hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma. * Extensive infarction or significant early ischemic changes on baseline imaging considered unsuitable for intravenous thrombolysis. * Severe hepatic dysfunction, severe renal dysfunction, severe infection, active malignancy, terminal illness, or other serious conditions with expected survival \<3 months. * Pregnancy, breastfeeding, or positive pregnancy test in women of childbearing potential. * Unable to complete 90-day follow-up, poor compliance, or other conditions considered unsuitable for study participation by the investigator.